Could Keighley have the winning formula?

Keighley Campbell  (left) with staff at HartBiologicals

Keighley Campbell (left) with staff at HartBiologicals

0
Have your say

A SCIENTIST and the company she works for are hoping to become award winners at a prestigious business competition.

Both Keighley Campbell and Hart Biologicals are shortlisted for the Bionow awards.

Keighley Campbell from Hart Biologicals

Keighley Campbell from Hart Biologicals

The competition is being held for the second year and this year’s contest will be held at the Baltic in Gateshead on Thursday, April 24.

The awards will celebrate the achievements of biomedical companies in the North

Organisers say they will highlight the strength and depth of the cluster and the diversity of the companies within the sector.

Keighley, 26, who works as a research and development manager for Hart Biologicals, which is based on the Queens Meadow business park in Hartlepool, is from east Durham.

Keighley Campbell from Hart Biologicals

Keighley Campbell from Hart Biologicals

She has been with the firm for four years and progressed from a scientist role to her current manager’s position.

She has been shortlisted for the most promising technologist award while the company is in the running in the export category.

Keighley has impressed on projects including one which is called the ultrasense range of coagulation reagents.

She explained that they related to testing in hospital, such as on a patient where a diagnostic test was needed to assess any defects in their blood coagulation.

Keighley Campbell from Hart Biologicals

Keighley Campbell from Hart Biologicals

Keighley has also worked on rotem platelet projects. These can be used where someone is involved in an accident. The system developed by Hart Biologicals helps medical experts to assess a patient’s blood straight away.

Keighley said: “When I first started I was a scientist and in 2012 I moved up to manager. Our managing director Alby Pattison put me forward for this award which is to do with technology which has had the greatest impact.”

Hart Biologicals manufactures reagents which are used to investigate the blood clotting function in patients taking blood thinning drugs such as warfarin, patients bleeding acutely during or after surgery or trauma, and those with blood coagulation disorders.

Last Autumn, the Mail revealed that Hart Biologicals was investing £1m in new equipment and facilities partly to link in with a new commercial contract in Germany.

Keighley Campbell from Hart Biologicals

Keighley Campbell from Hart Biologicals

The company also won the Exporter of the Year title at last year’s Hartlepool Business Awards.

Keighley Campbell from Hart Biologicals

Keighley Campbell from Hart Biologicals